4.51
+0.2(+4.64%)
Currency In USD
| Previous Close | 4.31 |
| Open | 4.25 |
| Day High | 4.54 |
| Day Low | 4.02 |
| 52-Week High | 8.56 |
| 52-Week Low | 1.78 |
| Volume | 453,910 |
| Average Volume | 282,128 |
| Market Cap | 94.64M |
| PE | -0.55 |
| EPS | -8.13 |
| Moving Average 50 Days | 2.99 |
| Moving Average 200 Days | 3.53 |
| Change | 0.2 |
If you invested $1000 in Adverum Biotechnologies, Inc. (ADVM) 10 years ago, it would be worth $51.96 as of September 28, 2025 at a share price of $4.51. Whereas If you bought $1000 worth of Adverum Biotechnologies, Inc. (ADVM) shares 5 years ago, it would be worth $43.62 as of September 28, 2025 at a share price of $4.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
GlobeNewswire Inc.
Sep 22, 2025 12:00 PM GMT
Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026)ARTEMIS topline data readout accelerated to 1Q 2027 REDWOOD CITY, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc.
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire Inc.
Aug 06, 2025 8:01 PM GMT
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Pr
Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
GlobeNewswire Inc.
May 14, 2025 8:05 PM GMT
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping cell-level transduction and aflibercept mRNA expres